TY - JOUR
T1 - Long-term safety and efficacy of teriflunomide Nine-year follow-up of the randomized TEMSO study
AU - O'Connor, Paul
AU - Comi, Giancarlo
AU - Freedman, Mark S.
AU - Miller, Aaron E.
AU - Kappos, Ludwig
AU - Bouchard, Jean-Pierre
AU - Lebrun-Frenay, Christine
AU - Mares, Jan
AU - Benamor, Myriam
AU - Thangavelu, Karthinathan
AU - Liang, Jinjun
AU - Truffinet, Philippe
AU - Lawson, Victoria J.
AU - Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group
AU - Hupperts, Raymond
AU - Wolinsky, Jerry S.
PY - 2016/3/8
Y1 - 2016/3/8
N2 - To report safety and efficacy outcomes from up to 9 years of treatment with teriflunomide in an extension (NCT00803049) of the pivotal phase 3 Teriflunomide Multiple Sclerosis Oral (TEMSO) trial (NCT00134563).A total of 742 patients entered the extension. Teriflunomide-treated patients continued the original dose; those previously receiving placebo were randomized 1:1 to teriflunomide 14 mg or 7 mg.By June 2013, median (maximum) teriflunomide exposure exceeded 190 (325) weeks per patient; 468 patients (63%) remained on treatment. Teriflunomide was well-tolerated with continued exposure. The most common adverse events (AEs) matched those in the core study. In extension year 1, first AEs of transient liver enzyme increases or reversible hair thinning were generally attributable to patients switching from placebo to teriflunomide. Approximately 11% of patients discontinued treatment owing to AEs. Twenty percent of patients experienced serious AEs. There were 3 deaths unrelated to teriflunomide. Soon after the extension started, annualized relapse rates and gadolinium-enhancing T1 lesion counts fell in patients switching from placebo to teriflunomide, remaining low thereafter. Disability remained stable in all treatment groups (median Expanded Disability Status Scale score ?2.5; probability of 12-week disability progression ?0.48).In the TEMSO extension, safety observations were consistent with the core trial, with no new or unexpected AEs in patients receiving teriflunomide for up to 9 years. Disease activity decreased in patients switching from placebo and remained low in patients continuing on teriflunomide.This study provides Class III evidence that long-term treatment with teriflunomide is well-tolerated and efficacy of teriflunomide is maintained long-term.? 2016 American Academy of Neurology.
AB - To report safety and efficacy outcomes from up to 9 years of treatment with teriflunomide in an extension (NCT00803049) of the pivotal phase 3 Teriflunomide Multiple Sclerosis Oral (TEMSO) trial (NCT00134563).A total of 742 patients entered the extension. Teriflunomide-treated patients continued the original dose; those previously receiving placebo were randomized 1:1 to teriflunomide 14 mg or 7 mg.By June 2013, median (maximum) teriflunomide exposure exceeded 190 (325) weeks per patient; 468 patients (63%) remained on treatment. Teriflunomide was well-tolerated with continued exposure. The most common adverse events (AEs) matched those in the core study. In extension year 1, first AEs of transient liver enzyme increases or reversible hair thinning were generally attributable to patients switching from placebo to teriflunomide. Approximately 11% of patients discontinued treatment owing to AEs. Twenty percent of patients experienced serious AEs. There were 3 deaths unrelated to teriflunomide. Soon after the extension started, annualized relapse rates and gadolinium-enhancing T1 lesion counts fell in patients switching from placebo to teriflunomide, remaining low thereafter. Disability remained stable in all treatment groups (median Expanded Disability Status Scale score ?2.5; probability of 12-week disability progression ?0.48).In the TEMSO extension, safety observations were consistent with the core trial, with no new or unexpected AEs in patients receiving teriflunomide for up to 9 years. Disease activity decreased in patients switching from placebo and remained low in patients continuing on teriflunomide.This study provides Class III evidence that long-term treatment with teriflunomide is well-tolerated and efficacy of teriflunomide is maintained long-term.? 2016 American Academy of Neurology.
KW - RELAPSING MULTIPLE-SCLEROSIS
KW - ORAL TERIFLUNOMIDE
KW - DOUBLE-BLIND
U2 - 10.1212/WNL.0000000000002441
DO - 10.1212/WNL.0000000000002441
M3 - Article
C2 - 26865517
SN - 0028-3878
VL - 86
SP - 920
EP - 930
JO - Neurology
JF - Neurology
IS - 10
ER -